APA-referens

Suzuki, T., Mizoshita, T., Sugiyama, T., Hirata, Y., Kimura, Y., Suzuki, Y., . . . Sasaki, M. (2019). Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment. Case Rep Gastroenterol.

Chicago-stil citat

Suzuki, Taketo, et al. "Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients With Loss of Response to Adalimumab, Especially in Cases Without Previous Infliximab Treatment." Case Rep Gastroenterol 2019.

MLA-referens

Suzuki, Taketo, et al. "Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients With Loss of Response to Adalimumab, Especially in Cases Without Previous Infliximab Treatment." Case Rep Gastroenterol 2019.

Varning: dessa hänvisningar är inte alltid fullständigt riktiga.